Ab-initio pharma | Formulation and GMP product manufacturing services for clinical trials in Australia

Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.

The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.

Visit The University of Sydney for more information.

Twitter: Sydney_Uni

LinkedIn: The University of Sydney

Consortium leadThe University of Sydney
Consortium membersAb Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia
MTPConnect grant$500,000
Industry contribution$500,000
Project durationJune 2018 - June 2021
ContactPaul Young, The University of Sydney - paul.young@sydney.edu.au